Pharma BD Deal Intelligence
BMS and Century Therapeutics entered a strategic collaboration to develop and commercialize up to four iPSC-derived allogeneic NK and T-cell therapy programs in hematologic malignancies and solid tumors. Century received $100M upfront plus a $50M equity investment, with up to $3B in additional payments plus royalties. UPDATE (terminated): On December 12, 2024 BMS notified Century that it would terminate the collaboration in its entirety, without cause, following an internal portfolio-prioritization review; the termination became effective March 12, 2025. Century recognized the remaining $109.2M deferred transaction price as one-time collaboration revenue in Q1 2025, with no further collaboration revenue expected. Century has since refocused lead asset CNTY-101 from oncology toward autoimmune disease (CALiPSO-1).